research use only

Enfuvirtide Acetate HIV inhibitor

Name: Enfuvirtide Acetate
Brand: Selleck Chemicals
SKU: E0005
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0005

Enfuvirtide Acetate (T20 Acetate, DP178 Acetate) is an HIV fusion inhibitor with ic50s of 13.63 nM and 30.21 nM on infection by HIV-1IIIB in MT-2 cells and HIV-1Bal in M7 cells, respectively.Solutions are unstable and should be fresh-prepared.

Chemical Structure

Molecular Weight: 4491.88

Jump to

Quality Control

Batch: Purity: 99.06%

99.06

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HCV Protease
Other HIV Inhibitors	Ebselen ABX464 Swertia Bimaculata Extract Zingibroside R1 Oxindole WAY-383487 Fostemsavir Tris CQ31 Ro24-7429

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (22.26 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	4491.88	Formula	C₂₀₄H₃₀₁N₅₁O₆₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	159519-65-0 (free base)	--		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

Read more about storage stability CAS number

Mechanism of Action

Targets/IC₅₀/Ki	HIV fusion
References	[1] https://pubmed.ncbi.nlm.nih.gov/26286358/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2021-11-23)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01836068	COMPLETED	HIV	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2013-06	EARLY_PHASE1
NCT01022476	COMPLETED	HIV Infection; Liver Failure; Evidence of Liver Transplantation	ANRS, Emerging Infectious Diseases	2010-05	PHASE1; PHASE2
NCT00537394	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2008-01	PHASE3
NCT00615134	COMPLETED	HIV Infections	Hoffmann-La Roche	2008-01	PHASE2
NCT00302822	COMPLETED	HIV Infections; AIDS	French National Agency for Research on AIDS and Viral Hepatitis	2006-04	PHASE3
NCT02582983	COMPLETED	HIV Infections	Hoffmann-La Roche	2004-02	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):